Determination Of The Risk Factors Of Pneumonia And The Evaluation Of The Cost Effectiveness Of Current Treatment Approach For Bacterial Pneumonia In Children Five Years And Younger by Abdulkader, Manhal A.
 i 
DETERMINATION OF THE RISK FACTORS OF 
PNEUMONIA AND THE EVALUATION OF THE COST 
EFFECTIVENESS OF CURRENT TREATMENT 
APPROACH FOR BACTERIAL PNEUMONIA IN 
CHILDREN FIVE YEARS AND YOUNGER 
 
 
 
 
 
By 
 
MANHAL A. ABDULKADER 
 
 
 
 
 
Thesis Submitted in fulfillment of the requirements for the 
degree of Master of Science 
(Pharmacy) 
 
 
 
 
November 2011 
 
  ii 
ACKNOWLEDGEMENT 
 
First and foremost, I would like to thank and praise Allah S.W.T., the Almighty, 
with whose blessings I was able to conduct and successfully complete this study. 
Whatever good this work contains is due to His blessings and whatever bad is due to me. 
 
I would like to take this opportunity to express my greatest gratitude to my 
supervisor, Assoc. Prof. Dr. Mohd Baidi Bahari, for his generous support and guidance. 
I can truly say that I would not be an independent and successful researcher as I am 
today without his kind guidance. 
  
My warmest gratitude also goes to my field supervisors, Dr.Hussain Imam Hj 
Muhammad Ismail and Prof. Dato’ Dr. Syed Mohamed Aljunid for their unwavering 
support, concern and encouragement, without which the endeavour would not have been 
possible.  I am also greatly indebted to Mr. Mohd Hafzi bin Jilani, the Director of the 
Medical Record Unit in the Pediatric Institute of Kuala Lumpur Hospital for his help. I 
shall also thank Dr.Zafar Ahamd and Dr. Amrizal Muhd Nur for their help in the 
economic field. My biggest thanks are also directed to Miss Subasyini 
Sivasupramaniam, a pharmacist in the Pharmacy Department of Kuala Lumpur Hospital 
for her help and interest. Special thanks also go to Dr. Haji Lailanor Haji Ibrahim, 
Deputy Director of Kuala Lumpur Hospital for his kind cooperation. 
 
 
  iii 
 Above all, I shall remain eternally grateful to all my family members, especially 
my wife, Dr. Duha Issa. She will always be my ray of light in darkness and my 
enormous source of inspiration and I dedicate all my effort and hard work to her. My 
daughter Aminah and my son Ahmad, they are the hope of my life, my kind parents, 
grandmother, aunt and my lovely sisters also have been my continuous big support that I 
will never forget as long as I am still alive. Without forgetting, I am also always grateful 
to my other family members, Dr. Issa Rahem who is my father-in-law, my brother-in-
law Dr. Ali Issa, and my mother-in-law for their kind support and patience, for whom 
there are no words of praises adequate enough for me to offer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  iv 
TABLE OF CONTENTS 
 
 
ACKNOWLEDGEMENT        ii 
TABLE OF CONTENT        v 
LIST OF TABLES         x 
LIST OF FIGURES         xii 
LIST OF ABBREVIATIONS       xiii 
LIST OF APPENDICES        xiv 
ABSTRAK          xv 
ABSTRACT          xvii 
 
CHAPTER I - INTRODUCTION        
1.1 BACKGROUND        1 
 1.1.1 Pneumonia Definition       2 
1.2 STUDY JUSTIFICATION       4 
1.3 STUDY OBJECTIVES                                                                                  5 
1.3.1 General Objectives                                                                                5                     
1.3.2 Specific Objectives                              5 
1.4 LITERATURE REVIEW       7 
1.4.1 Epidemiology of Pneumonia      7 
1.4.2 Risk Factors of Pneumonia      11 
1.4.2.1 Lack of breast feeding     12 
1.4.2.2 Incomplete immunization     15 
  v 
1.4.2.3 Low birth weight      17 
1.4.2.4 Preterm birth       20 
1.4.2.5 Low weight for age      20 
1.4.2.6 Day care attendance      22 
1.4.2.7 Young maternal age      23 
1.4.2.8 Parental smoking habit     24 
1.4.3 Clinical Types of Pneumonia      26 
1.4.4 Etiology of Pneumonia      27 
1.4.5 Signs and Symptoms       30 
1.4.5.1 Newborn       30 
1.4.5.2 Older infants       30 
1.4.5.3 Toddlers and preschoolers     31 
1.4.5.4 Older children and adolescents    31 
1.4.5.5 All children       31 
1.4.6 Diagnosis        31 
1.4.6.1 Pneumonia diagnosis base on rapid breathing  32 
1.4.6.2 Pneumonia diagnosis based on chest wall indrawing  32 
1.4.7 Investigations        33 
1.4.7.1 Laboratory studies      34 
1.4.7.2 Imaging studies      37 
1.4.8 Management of Pneumonia      39 
1.4.8.1 Assessment of pneumonia severity    40 
1.4.8.2 Assessment of oxygenation     42 
1.4.8.3 Criteria for hospitalization     42 
  vi 
1.4.8.4 Antibiotic therapy      43 
1.4.9 Cost of Pneumonia Infection      51 
1.4.10 Prevention of Pneumonia      55 
 
CHAPTER II - METHODOLOGY       
2.1 STUDY DESIGN          60 
2.2  SETTING         60 
2.3 SUBJECTS         60 
 2.3.1 Selection Criteria       60 
 2.3.1.1  Inclusion criteria     60 
 2.3.1.2  Exclusion criteria     61 
 2.3.2 Sample Size        61 
2.4 CONTROLS         62 
2.5 DATA COLLECTION       63 
 2.5.1 Case-Control study       63 
 2.5.2 Cost Effectiveness       65 
  2.5.2.1  Cost    66 
   2.5.2.1.1 Bottom up costing method  66 
              2.5.2.1.2 Treatment cost     67                                                                                        
              2.5.2.1.3  Staff cost  67 
              2.5.2.1.4 Investigations cost  68 
              2.5.2.1.5 Hospital stay cost  69 
   2.5.2.1.5 a Clinical Cost Modeling software (CCM)  69 
   2.5.2.1.5 b CCM Methodology  70 
  vii 
  2.5.2.3 Effectiveness    70 
  2.5.2.4 Cost Effectiveness Ratio (CER)  71 
 2.5.3 Flow Chart of Data Collection                 73 
2.6 STATISTICAL TESTS       74 
 2.6.1 Regression Analysis       74 
 2.6.1.1 Binary logistic regression analysis     74 
2.7 STUDY APPROVAL        75 
 
CHAPTER III - RESULTS     
3.1 DEMOGRAPHICS OF PATIENTS      76 
3.1.3 Types of Pneumonia       80 
3.2 RISK FACTORS        81 
3.2.1 History of Hospitalization      83 
3.2.2 History of Previous Pneumonia or Other Respiratory Illness 84 
3.2.3 Association of risk factors with pneumonia    85 
3.2.4 Binary Logistic Regression      86 
3.3 COST EVALUATION       88
 3.3.1 Drug Cost        88 
3.3.2 Physician Cost       90 
3.3.3 Pharmacist Cost       91
 3.3.4 Nurse Cost        92 
3.3.5 Cost of Hospital Stay       92 
3.3.6 Investigation Cost       92 
3.3.7 Cost Effectiveness Evaluation     93 
  viii 
  3.3.7.1 Direct medical cost      93 
  3.3.7.2 Effectiveness measure     94 
  3.3.7.3 Cost effectiveness ratio and ICER    95 
3.4 ANTIBIOTICS USE ACCORDING TO AGE GROUPS   96 
 
CHAPTER IV – DISCUSSION    
4.1 PATIENT DEMOGRAPHICS                 98 
4.2 RISK FACTORS        101 
4.2.1 Incomplete Immunization      101 
4.2.2 Lack of Breast Feeding      103 
4.2.3 Day Care Attendance       105 
4.2.4 Parental Smoking       108 
4.2.5 Low Weight for Age       109 
4.2.6 Other Risk Factors       111 
4.3 PHARMACOECONOMICS – COST EFFECTIVENESS    112 
 EVALUATION  
 
4.3.1 Treatment Cost       113
 4.3.2 Investigation Cost       114 
4.3.3 Cost of Hospital Stay       115 
4.3.4 Cost Effectiveness Analysis      118 
4.4 ANTIBIOTIC CHOICE, AGE GROUPS AND CONCORDANCE WITH  
GUIDLINES         121 
4.5 STUDY LIMITATION       124 
 
  ix 
CHAPTER VI - CONCLUSION       127 
5.1 RECOMMENDATION       129 
REFERENCES          132 
APPENDICES         162 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  x 
LIST OF TABLES 
 
Table 1.1 Estimates of incidence and number of new cases per year of  8 
 clinical pneumonia in children less than 5 years age, by WHO 
  regions 
        
Table 1.2 The fifteenth countries with the highest estimated absolute number  10 
 of new clinical pneumonia cases 
 
Table 1.3 Pathogens causing pneumonia based on age groups in Malaysia 29 
Table 1.4 Definition of Tachypnoea      40 
 Table 1.5 Assessment of pneumonia severity among infants up to two  40 
  months old  
          
 Table 1.6 Assessment of pneumonia severity in children age 2 months 41  
 to 5 years old by WHO 
         
Table 1.7 Susceptibility of Streptococcus pneumoniae found in Malaysia 47 
 
Table 1.8 Susceptibility of worldwide isolates of Streptococcus pneumoniae  48 
 
Table 1.9 Susceptibility of Streptococcus pneumoniae in different  49  
  countries          
   
Table 1.10  Recommended antibiotics for inpatient management of   49 
             children with severe pneumonia 
      
Table 3.1 Demographics of patients and maternal age      76 
Table 3.2 groups of age, weight, race and gender    78 
Table 3.3 Pneumonia types       80 
Table 3.4 Risk factors distribution       81 
Table 3.5 Hospitalization history      83 
Table 3.6 History of respiratory illness and co-morbidities for the case group 84 
Table 3.7 Pneumonia risk factors analysis by Chi-square Cross tabulation 85 
Table 3.8 Binary Logistic Regression (Pneumonia & the Risk Predictors) 87 
  xi 
Table 3.9 Number of patients in each antibiotic group    88 
Table 3.10 Cost between main antibiotic groups     89 
Table 3.11 Cost of treatment, staff and health care resource (Direct Cost) 90 
Table 3.12 Direct Cost compartments between the main two antibiotics groups 94 
Table 3.13 Antibiotic use according to age groups                                               96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  xii 
LIST OF FIGURES 
 
Figure 2.1 Methods to reduce bias in case control studies   63 
Figure 2.2 Flow chart of study design and methodology      73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  xiii 
LIST OF ABBREVIATIONS  
 
AIDS  Acquired Immune Deficiency Syndrome        
ALRI  Acute Lower Respiratory Tract Infection        
ARI  Acute Respiratory Infection       
AM  Alveolar Macrophages       
CBC  Complete Blood Count       
CEA  Cost Effectiveness Analysis       
CER  Cost Effectiveness Ratio       
CHERG Child Health Epidemiology Reference Group 
CI  Confidence Interval 
COPD  Chronic Obstructive Airway Disease 
CRP  C Reactive Protein 
C/S  Culture and Sensitivity Test 
CS  Cigarette Smoking  
DF  Degree of Freedom 
DPT  Diphtheria, Pertussis and Tetanus 
ESR  Erythrocyte Sedimentation Rate 
Exp. B  Exponential B (Odds Ratio) 
FBC  Full Blood Count 
FEV  Forced Expiratory Volume 
FVC  Forced Vital Capacity  
CPGs  Clinical Practice Guidelines 
Hib  Haemophilus influenzae type B 
HKL  Kuala Lumpur Hospital 
ICER  Incremental Cost Effectiveness Ratio 
IDSA  Infectious Disease Society of America 
IPHKL Institute of Pediatric in Kuala Lumpur Hospital 
K.-S Test Kolmogorov–Smirnov test  
LOS  Length of Stay 
MMR  Measles, Mumps and Rubella 
OR  Odds Ratio 
OPV  Oral Polio Vaccine 
MYR  Malaysian Ringgit 
RR  Relative Risk 
SE  Standard Error 
SGA   Small for Gestational Age 
SHS  Second Hand Smoking 
UNICEF The United Nations of Children Fund 
WHO  World Health Organization 
 
  
 
  xiv 
LIST OF APPENDICES 
 
Appendix A Data Collection Form for Case and Control Groups      161 
Appendix B Study Approval          170 
Appendix C Malaysian Clinical Practice Guidelines on Pneumonia in  172 
  Children, 2002.           
 
Appendix D List of Drugs Cost       182 
Appendix E List of Staff Salary       186 
Appendix F List of Investigations Cost      188 
Appendix G Calculations of CEA       190 
Appendix H Growth Chart for Boys and Girls     192 
Appendix I Vaccination Schedule        197 
 
 Appendix J Calculations of Staff Cost      199 
Appendix K List of Publications       202 
Appendix L Certificate of Best Poster Presentation Award and Conference 
Participation Certificate       205 
 
Appendix M Certificate of Participation in NIH Scientific Meeting and  
4
th
 NCCR Conference       208 
 
Appendix N Certification of Achievement Good Clinical Practice (GCP) 210 
Appendix O Data for CCM Costing Method     212 
Appendix P Effectiveness        217 
Appendix Q Antibiotic Resistance in IPHKL     219 
Appendix R Certificate of Pre Viva Presentation     223 
Appendix S Clinical Cost Modeling Details     224 
 
  xv 
KAJIAN BAGI MENENTUKAN FAKTOR-FACTOR RISIKO RADANG PARU-
PARU DAN PENILAIAN KOS KEBERKESANAN RAWATAN SEDIA ADA 
RADANG PARU-PARU DISEBABKAN BAKTERIA DI KALANGAN  KANAK-
KANAK BERUMUR LIMA TAHUN DAN KEBAWAH 
ABSTRAK 
Pneumonia  atau radang paru-paru, merupakan salah satu penyebab utama morbiditi dan 
kematian, terutama sekali di negara-negara membangun. Pencegahan pneumonia dan 
kecacatan disebabkan olehnya boleh dicapai dengan mengurangkan faktor-faktor risiko 
penyebab pneumonia dan menilai golongan yang berisiko tinggi. Penilaian faktor-faktor 
risiko tersebut adalah salah satu dari tiga matlamat kajian kes kawalan berdasarkan umur 
dan jantina secara retrospektif ini. Seramai 260 orang kanak-kanak berumur lima tahun 
dan kebawah yang disahkan menghidap pneumonia mengikut panduan kod ICD-10 
terlibat dalam kajian, 43% (n=113) dari mereka menghidap pneumonia disebabkan virus 
dan 57% (n=147) lagi disebabkan oleh bakteria. Faktor-faktor risiko pneumonia telah 
diuji menggunakan ‘Chi-square’ dan ‘Binary Logistic Regression’. Imunisasi tidak 
lengkap telah ditemui sebagai alat ramalan risiko yang paling penting berbanding faktor-
faktor risiko lain yang telah dianalisis (OR=3.71, p<0.001). Faktor-faktor lain yang 
menjadi penting dalam kajian ini ialah kehadiran ke pusat jagaan harian kanak-kanak 
(p=0.001), kurang berat badan berbanding umur (p=0.001), kurang penyusuan ibu 
(p=0.016) dan bapa perokok (p=0.04). Matlamat kedua kajian ini  adalah untuk 
mengenal pasti antibiotik pilihan yang paling berkesan dan berkos rendah di antara 
jenis-jenis antibiotik yang lain untuk rawatan pneumonia disebabkan bakteria. Hanya 
dua antibiotik sahaja yang dimasukkan ke dalam analisis iaitu cefuroxime dan C-
penicillin mengikut sampel yang didedahkan oleh kedua-dua ubat. Bagi kumpulan 
cefuroxime, purata jumlah keseluruhan kos rawatan ialah RM 838.90 (IQR. 787.9, 
  xvi 
1834.57), dan bagi kumpulan C-penicillin, puratanya ialah RM 1153.85 (IQR. 791.61, 
1523.9). Penggunaan cefuroxime menghasilkan kejayaan rawatan pesakit yang lebih 
baik (84% berbanding 73% kadar kejayaan rawatan) dan dengan kos yang lebih rendah. 
Nisbah keberkesanan kos untuk cefuroxime dan C-penicillin ialah masing-masing RM 
998.70 dan RM 1580.60 yang menunjukkan bahawa cefuroxime mempunyai kos 
keberkesanan lebih rendah berbanding C-penicillin. Nilai ICER bersamaan - 2,863, di 
mana nilai negative ICER menunjukkan kesan penjimatan. Kesinambungan rawatan 
terkini dengan garis panduan kebangsaan adalah matlamat lain kajian ini, dan ia 
mendedahkan bahawa 82% (n=127) daripada kes pneumonia disebabkan bakteria telah 
dirawat mengikut garis panduan.  
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DETERMINATION OF THE RISK FACTORS OF PNEUMONIA AND THE 
EVALUATION OF THE COST EFFECTIVENESS OF CURRENT 
TREATMENT APPROACH FOR BACTERIAL PNEUMONIA IN CHILDREN 
FIVE YEARS AND YOUNGER 
 
ABSTRACT 
Pneumonia is a major cause of morbidity and mortality especially in developing 
countries. The prevention of pneumonia and its later disabilities can be achieved by the 
reduction of risk factors and evaluating subjects of high risk. Risk factors evaluation was 
one of the three aims of this retrospective age and gender matched case control study. A 
total of 260 children five years and younger diagnosed with pneumonia according to 
ICD-10 were involved, 43% of them (n = 113) having pneumonia of viral origin and 
57% (n = 147) having bacterial pneumonia. Pneumonia risk factors were determined 
using Chi-square and Binary Logistic Regression. Incomplete immunization found to be 
the most significant risk predictor among all the analyzed factors (OR = 3.71, p< 0.001). 
The other factors that were significant in this study are day care attendance (p = 0.001), 
low weight for age (p =0.001), lack of breast feeding (p = 0.016) and paternal smoking 
(p = 0.04). The second objective of this study was to determine the most cost effective 
choice among the current antibiotics used for bacterial pneumonia management. The 
only two antibiotics that were evaluated are cefuroxime and C-penicillin according to 
the revealing samples of the both drugs. For the cefuroxime group the median of the 
total management cost is MYR 838.90 (IQR. 787.90, 1834.57), for the C-penicillin 
group the median is MYR 1153.85 (IQR. 791.61, 1523.9). Cefuroxime use resulted in 
better patient outcome (84% versus 73% treatment success rate) and at lower cost. The 
cost effectiveness ratio for cefuroxime and C-penicillin are 998.70 and 1580.60 
respectively, this indicate that cefuroxime is more cost effective than C-penicillin. The 
  xviii 
incremental cost effectiveness ratio is equal to - 2,863, minus value of ICER indicate 
saving effects. Concordance of the current treatment pattern with the national guidelines 
was the third objective of this study, and it reveals that about 82% (n = 127) of the 
bacterial pneumonia cases were treated according to the guidelines.  
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CHAPTER I 
INTRODUCTION 
 
1.1    BACKGROUND 
Acute Lower Respiratory Tract Infection is one of the three main causes of death 
among children globally. Lower Respiratory Tract Infection (LRTI) is the third leading 
cause of death among children worldwide and it is the first leading cause of death among 
children in low income countries (WHO, World Health Statistics 2008). The most 
common severe form of LRTI is pneumonia. It is responsible for the two million deaths 
among children under five years of age worldwide annually (Williams et al., 2002). The 
estimated annual treatment costs for treating Community Acquired Pneumonia (CAP) in 
the U.S. alone is USD12.2 billion (Colice et al., 2004). In developing countries, more 
than 25% of children have an episode of clinical pneumonia for the first 5 years of their 
life. Many of these disease episodes are severe and potentially fatal (Rudan et al., 2004). 
Therefore, this has led to the conclusion that pneumonia is the cause of 21% of child 
deaths in the developing world (Williams et al., 2002) which makes pneumonia as the 
largest single cause of childhood mortality. In Malaysia, the prevalence of ARI among 
children under five years of age is estimated to be 28% to 39.3% (Azizi et al., 2002, 
Malaysian CPGs on Pneumonia and Respiratory Tract Infections in Children, 2002), and 
pneumonia is the third leading cause of death among Malaysian children under five 
(Hussain et al., 2008). 
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1.1.1 Pneumonia Definition 
Pneumonia is an inflammation and consolidation of the lung tissue due to an 
infectious agent. The inflammation involves the lung tissues and the terminal airspaces. 
The inflammatory cascade triggers the leakage of plasma and the loss of surfactant, 
thereby resulting in air loss and consolidation. 
 
An inhaled infectious organism must bypass the host's normal non-immune and 
immune defense mechanisms in order to trigger the infection of pneumonia. The non-
immune mechanisms include the aerodynamic filtering of inhaled particles based on the 
size, shape, and the electrostatic charges: the cough reflex, mucociliary clearance, and 
several secreted substances (eg, lysozymes, complement, defensins). Macrophages, 
neutrophils, lymphocytes, and eosinophils carry out the immune mediated host defense 
(Dennis, 2009). 
 
Pneumonia can result from a variety of causes, including infection with bacteria, 
viruses, fungi, parasites, and chemical or physical injury to the lungs. Its cause may also 
be officially described as idiopathic, which is unknown when infectious causes have 
been excluded (Nicholas and Joseph, 2009). Pneumonia that develops outside the 
hospital setting is considered as community acquired pneumonia while pneumonia that 
develops 48 hours or more after admission to the hospital is termed as nosocomial or 
hospital acquired pneumonia (American Thoracic Society and the Infectious Diseases 
Society of America, 2005). Community acquired pneumonia is divided into 2 groups, 
typical and atypical. Typical organisms include S pneumoniae (pneumococcus), 
Haemophilus and Staphylococcus species. Atypical refers to pneumonia caused by 
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Legionella, Mycoplasma, and Chlamydia species (Woodhead, 2002). In developing 
countries, the case of fatality rate among children with viral pneumonia ranges from 1.0 
to 7.3 percent (Stensballe, Devasundaram, and Simoes, 2003), with bacterial pneumonia 
ranging from 10 to 14 percent and with mixed viral and bacterial infections from 16 to 
18 percent (Ghafoor et al., 1990). 
 
Therefore, a prompt treatment of pneumonia with a full course of appropriate 
antibiotics is lifesaving. In fact, an early treatment is most vital in order to improve the 
chances of avoiding the development of serious complications and deaths. Although 
drug management is available, only about half of the children infected with pneumonia 
receive appropriate medical care, and according to the available information, it was 
discovered that less than 20 per cent of children with pneumonia received antibiotics 
treatment as recommended (WHO/UNICEF, 2006). Expanding treatment coverage is not 
impossible, and even could be done at a relatively low cost. It is estimated that if the 
antibiotic treatment were delivered to all children with pneumonia, this will help in 
saving the life of around 600,000 children each year, at a cost of USD 600 million 
(Gareth et al., 2003). In addition, if efforts for protection could be made through 
delivering preventive intervention against death from pneumonia globally, this will be 
able to double the number of lives saved up to 1.3 million. The act of identifying the risk 
factors and intervening modifiable risk factors is anticipated to play a greater role in 
reducing the number of deaths from pneumonia. Therefore, this study was designed to 
investigate the influencing risk factors and to evaluate the cost effectiveness of 
antibiotics usage. 
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1.2    STUDY JUSTIFICATION 
Human health had improved dramatically during the last century, yet grave 
inequities in health still persist. It is well known that pneumonia and other respiratory 
infections are the main causes of morbidity and mortality among children worldwide. 
They occupy most of the consultation time at the primary care as well as in the hospital 
setting (Azizi et al., 2002, Malaysian CPGs on Pneumonia and Respiratory Tract 
Infections in Children, 2002). The effort to manage these ailments imposes enormous 
burden on health resources. It is undeniable that pneumonia is a fatal disease. It kills 
more children than any other illness, more than AIDS, malaria and measles combined 
(WHO/ UNICEF, 2006). It has been estimated that over two million children had died 
from pneumonia each year accounting for almost one for every five deaths worldwide. 
Yet, not much attention is paid to this fatal disease (WHO/ UNICEF, 2006). Most of the 
previous researches on pneumonia focused only on the general aspects of management. 
However, this research is focusing on the treatment and the risk factors of pneumonia. 
The overuse and misuse of antibiotics has contributed to the increase in bacterial 
resistance patterns (Ball et al., 2002), as well as associated with increased costs, 
including the cost of the antibiotics and the increase in overall costs of medical care 
because of treatment failures and adverse events, particularly if hospitalization is 
required (Nicolau, 2002). Hence, resources must be deployed effectively in order to 
make a progress in health, to meet new challenges and to redress inequities. 
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This requires knowledge about which therapeutic interventions will actually work 
to contribute information on the total cost involved. This can be achieved through the 
application of cost effectiveness analysis of various antibiotics, which will be examined 
in this research. 
 
1.3    OBJECTIVES OF STUDY 
1.3.1    General Objectives 
The general objectives of this study are, firstly, to determine the risk factors of 
pneumonia (both viral and bacterial) among children five years old and younger 
hospitalized during year 2008 in the pediatric institute of Hospital Kuala Lumpur (HKL) 
and secondly, to evaluate the cost effectiveness of antibiotics prescribed for hospitalized 
children in the pediatric institute and the concordance of antibiotic used for bacterial 
pneumonia with the Malaysian Clinical Practice Guidelines on Pneumonia and 
Respiratory Tract Infections in Children, 2002. 
 
1.3.2    Specific Objectives 
The specific objectives are as follows: 
 To determine the most influencing risk factor. 
 To determine other modifiable risk factors  
 To determine influencing non-modifiable risk factors which will help in defining 
individuals and groups at higher risk for whom controlling or treating their 
modifiable risk factors are of priority. 
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 To calculate the cost effectiveness of antibiotics prescribed for hospitalized 
children with bacterial pneumonia. 
 To evaluate antibiotics prescribed for bacterial pneumonia management 
according to age groups for children 5 years and younger in concordance with 
the national guidelines (Azizi et al., 2002, Malaysian CPGs on Pneumonia and 
Respiratory Tract Infections in Children, 2002). 
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1.4    LITERATURE REVIEW 
 Childhood pneumonia is one of the largest causes of morbidity among children 
five years and younger. It is responsible for almost one fifth of total mortality in this age 
group. Global health care agencies have focused on this disease and direct their support 
at the international., practical, academic and research level. However, during the search 
in the literature for this study, there were no much studies, systematic review or wide 
cohort study at the national level addressing the important issues of pneumonia in 
children (issues such as diagnosis, programmes for prevention, management, risk factors 
determination and pneumonia burden in Malaysia). 
 
  Even globally, most of the studies founded about the risk factors of pneumonia 
were for the period from 1990 - 2000. There are only few recent studies to address the 
issue of pneumonia risk factors among children. At the national level, the presence of 
the Malaysian Clinical Practice Guidelines on Pneumonia and Respiratory tract 
infections is valuable. These guidelines provide a comprehensive guidance in the local 
context. Updating these Guidelines is also one of the issues that need to be highlighted, 
as it belongs to year 2002, by now the etiology of pneumonia could have been changed 
which may affect the clinical applicability of these guidelines. 
 
1.4.1    Epidemiology of Pneumonia 
Rudan et al., (2004) calculated and published the first global estimate of the 
incidence of clinical pneumonia among children aged less than 5 years for the year 2000. 
It was discovered that the estimated median incidence for developing countries was 0.28 
episodes per child per year. WHO, on the other hand, came up with a calculation for the 
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incidence of clinical pneumonia among children aged less than 5 years in developing 
countries worldwide (WHO regions include the African Region, the Region of the 
Americas, South-East Asia Region, European Region, Eastern Mediterranean Region 
and the Western Pacific Region) which is close to 0.29 episodes per child per year 
(Table 1.1). This equates to 151.8 million new cases every year of which thirteen million 
(8.7%) are severe enough and require hospitalization.  
 
It was reported that an additional 4 million cases occurred in developed countries 
worldwide. The incidence of clinical pneumonia was estimated to be highest in South 
East Asia (0.36 episodes per child per year) and lowest in European regions (0.06 
episodes per child per year).  
 
Table 1.1: Estimates of Incidence and Number of New Cases per Year of 
Clinical Pneumonia among Children Less Than 5 Years Old (WHO Regions) 
 
 
WHO Regions 
 
Total 
population 
aged 0-4 
years 
(million) 
 
Estimated incidence 
(episode/child/year) 
 
Estimated 
 number 
 of new  
cases 
Africa 105.62 0.33 35.13 
America 75.78 010 7.84 
Eastern Mediterranean 69.77 0.28 19.67 
European 51.96 0.06 3.03 
South East Asia 168.74 0.36 60.95 
Western Pacific 133.05 0.22 29.07 
Total  
(Developing Countries) 
523.31 0.29 151.76 
Total 
 (Developed Countries) 
81.61 0.05 4.08 
Total 604.93 0.26 155.84 
 
WHO Bulletin: Epidemiology and etiology of childhood pneumonia, 
Rudan et al., 2008. 
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The high incidence of pneumonia worldwide makes it a major public health interest. 
In order to assess the distribution of 156 million episodes according to regions and 
countries, WHO established the Child Health Epidemiology Reference Group 
(CHERG). This consists of a group of independent technical experts. CHERG has 
systematically reviewed and improved the collection of data, methods and assumptions 
underlying the estimates of the distribution of the main causes of death.  
 
As a result, they provided a new regional and country pneumonia morbidity 
estimates for the year 2000 (despite being relatively old it is the latest global estimate for 
pneumonia released by WHO). They reviewed current understanding of the distribution 
of pneumonia’s etiological agents among children aged less than 5 years. They 
determined the countries with the highest predicted number of new pneumonia episodes 
and their respective incidence (Table 1.2). These 15 countries accounted for 74% (115.3 
million episodes) of the total estimated 156 million global episodes. 
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Table 1.2: The fifteenth Countries with the Highest Estimated Absolute Number of 
New Clinical Pneumonia Cases 
 
Country 
Predicted No. of 
New Cases 
(Million) 
Estimated  Incidence 
(episode/child/year) 
India 43.0 0.37 
China 21.1 0.22 
Pakistan 9.8 0.41 
Bangladesh 6.4 0.41 
Nigeria 6.1 0.34 
Indonesia 6.0 0.28 
Ethiopia 3.9 0.35 
Congo 3.9 0.39 
Viet Nam 2.9 0.35 
Philippine 2.7 0.27 
Sudan 2.0 0.48 
Afghanistan 2.0 0.45 
Tanzania 1.9 0.33 
Myanmar 1.8 0.34 
Brazil 1.8 0.11 
 
WHO Bulletin: Epidemiology and etiology of childhood pneumonia, 
Rudan et al., 2008. 
 
 
Annually, more than half of the world’s new pneumonia cases were concentrated in 
three countries where 44% of the world’s children aged below 5 years live. These 
countries are India (43 million), China (21 million) and Pakistan (10 million) while 
Bangladesh, Indonesia and Nigeria each had 6 million cases (United Nations 
Millennium, 2008). The incidence of pneumonia in Malaysia, as part of Western Pacific, 
is 0.22 (22%) episodes/child/year which was considered high by the WHO. However, 
there were no statistics of pneumonia cases in Malaysia specifically. A study conducted 
by Maimunah et al., (1997) discovered that the prevalence of ARI among children below 
the age of five years was estimated to be between 28% - 39.3%.  
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1.4.2    Risk Factors 
A risk factor is defined as an attribute that is associated with the increased risk of an 
outcome.  The relationship between the risk factor and the outcome may be either causal 
or non-causal. Causal risk factors are determinants of the outcome, and a successful 
intervention to reduce exposure to them would improve the outcomes. However, a non-
causal risk factor may be associated with the outcome through confounding or reverse 
causation. Interventions to reduce exposure to non-causal risk factors would not 
necessarily improve the outcomes. In addition to this, previous studies had tested some 
of the risk factors of pneumonia (Azizi et al., 1995; Choo et al., 1998; Luiz et al., 2004; 
Ana et al 2004; Best et al., 2008), but still there is a need to confirm their findings and 
searching the presence of other risk factors. The Malaysian Clinical Practice Guidelines 
on Pneumonia and Respiratory Tract Infections in Children for the year 2002 had listed 
the following risk factors. 
 
i. Low weight for age (Anon, 2003) 
ii.  Lack of breast feeding (Karalanglin et al., 2009).  
iii.  Failure to complete immunization (Hassan and Al-Sadoon, 2001).  
iv.  Low birth weight (Luiz  et al., 2004). 
 
Other possible factors that may have increased the risk of patients to develop 
pneumonia were documented by some studies. These factors are: 
 
i. Young maternal age (Luiz et al., 2004).  
ii. Attendance at day care centres (Ana et al., 2004). 
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iii. Paternal smoking (Best et al., 2008; Peat et al., 2007). 
iv. Maternal smoking (Strachan and Cook, 1997; Peat et al., 2007; Brenda, 
2008).  
v. Pre term birth (Gessner, Castrodale, and Soriano, 2005). 
 
Despite recent advances in the treatment of pneumonia which offer hope in 
reducing its devastating effect, prevention still remain an important approach to reduce 
the incidence, recurrence and mortality of pneumonia (Lorente, Blot, and Rello, 2010; 
Hallie and James, 2010). The prevention of pneumonia and its later complications can be 
achieved by the reduction of risk factors, specifically the modifiable risk factors. 
However, non modifiable risk factors will also help to prevent pneumonia through the 
evaluation of those subjects of high risk who will have a priority in the prevention and 
management. 
 
1.4.2.1    Lack of Breast Feeding  
Infection still constitute a heavy burden and still remain as a major cause of 
morbidity and mortality worldwide despite current advances in medicine, nutrition, 
hygiene and anti infective therapy. The high susceptibility of neonates and infants to 
infection could be in part due to some of the contributing factors that predispose to 
infection. However, there is a clear deficit in various aspects of neonates’ and infants’ 
immune system which could be the main cause of this increase in susceptibility to 
infection. Knowing that there is a direct relation between infants’ immune system 
development and the increase risk of infection among the newborns, infants and children 
demand greater understanding of breast milk immunological advantages. Breast feeding 
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is strongly recommended for babies during the first months of life. In addition to the 
immunologic advantages of breast milk, it contains all the newborn’s nutritional needs. 
There is evidence that breast feeding decreases the risk of infections in children (Cesar 
et al., 1999; John et al., 1997), although some authors suggested that the effect of breast 
feeding might be more important in decreasing the severity of infections (measured by 
the rate of hospitalization) than in reducing the risk of infection (Chen, 1994).  
 
Breast feeding provides immunity and protects children against ALRI through 
breast milk's
 
unique anti-infective properties (Robert and Camille, 2007). It provides 
passive protection
 
against pathogens (antibacterial and antiviral substances including
 
secretory immunoglobulin A, lactoferrin, oligosaccharides, and
 
cells which include 
macrophages, lymphocytes, and neutrophils), stimulants
 
of the infant's immune system, 
and the bifidus factor which
 
inhibits colonization by Gram negative species (Hanson et 
al., 2004).  
 
 In short, immunologic advantages of breastfeeding can be measured in terms of 
mortality and risk of infection among breastfed infants compared to non-breastfed 
infants. Three studies were conducted to provide information on ALRI (including 
pneumonia) and its related mortality in relation to breast feeding status. In major 
Brazilian case control study with large sample size, the data of infants who died of ALRI 
and the data of control subjects taken from the same community were compared. The 
odd ratio for lack of breast feeding was 3.6. This indicate that children who were not 
breast fed have about three and half times more likely to die of ALRI than those who 
received breast milk. The result was achieved after excluding of the other confounding 
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factor (Victora et al., 1987). A case control study from Tanzania, on the other hand 
showed a relative risk about 1.7 for non breast fed children. Confounding factors were 
not controlled and this may reduce accuracy of the result. The third study is cohort study 
from Philippines. The relative risk for non breast fed children was 1.05 which indicates 
no association between lack of breast feeding and ALRI (Yoon, 1996). Other studies 
were conducted to provide the evidence on the association of nutrition interventions 
(including breast feeding) and reduction of respiratory infection risk (Froozani et al., 
1999; Alvarado et al., 1999; Vitolo et al., 2005). However the above controversy may 
not be resolved by the results of these studies as they did not distinguish upper from 
lower respiratory tract infections. Hence the mentioned studies can not be used as 
evidence for this study which is focusing on pneumonia only (the main presentation of 
LRTI). PROBIT (Promotion of Breastfeeding Intervention Trial) is a large cluster 
randomized trial in the Republic of Belarus. The effect of breastfeeding promotion on 
ALRI outcomes was presented by 15% decrease in LRTI hospitalization (Kramer et al., 
2001). More recently, a critical review of randomized trials of the effect of nutritional 
interventions on ALRI morbidity and mortality was done. This review included meta 
analyses and large scale randomized controlled trials on the effect of nutritional 
interventions (including breastfeeding promotion) on ALRI morbidity and mortality. 
This was based primarily on several systematic reviews that formed the evidence base 
for the Lancet Undernutrition Series (LUS). They concluded that exclusive breastfeeding 
promotion reduces ALRI morbidity (Roth et al., 2008). The other evidence is the global 
estimates of the effects of maternal and child undernutrition on infants health 
consequences. It revealed that lack of exclusive breastfeeding in the first half of infancy 
is a risk factor for ALRI incidence, morbidity and death (Black et al., 2008). 
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1.4.2.2    Incomplete Immunization 
Most of the studies that were conducted for evaluating the association between 
immunization and respiratory infections including pneumonia, involved only one type of 
vaccines. This study evaluated three vaccines that shown to have association with 
pneumonia. The vaccines are DPT-Hib, OPV and MMR. During the search in literature, 
most of the papers found were about the new pneumococcal conjugate vaccine (PCVs) 
which is not included in this study as it is unavailable in the public health sector of 
Malaysia. Few papers focusing on Hib and measles vaccinations were also found. In 
systematic review of observation studies, the association of mortality reduction with 
childhood vaccines was examined. This includes 24 studies with robust methodologies 
on measles vaccine.  There was 31- 46% reduction in mortality (after elimination of 
methodologically low quality data). This reduction was attributed to the reduction of 
measles disease and its complications, mainly pneumonia (Cooper et al., 2003). 
 
A recent systematic review of published randomized controlled trials (RCTs) and 
quasi experimental (QE) studies was conducted to determine the effectiveness of 
measles vaccine. Meta analysis of these studies found that vaccination was 85% [95% 
confidence interval (CI) 83–87] effective in preventing measles disease (Sudfeld, Navar, 
and Halsey, 2010). However this review did not focus on prevention of pneumonia or 
LRTIs as one of the complications of measles. The WHO 2008 report has cited and 
categorized pneumonia risk factors and lack of measles immunization was considered as 
one of the definite risk factors for pneumonia (Rudan et al., 2008). 
 
  16 
On the other hand, the importance of Hib vaccine in the prevention of pneumonia is 
related the organisms commonly causes pneumonia in this age group, those are 
Haemophilus influenzae type b (Hib) and Streptococcus pneumonia (Sazwal and Black, 
2003). Hence, the risk of pneumonia infection increases if this vaccine missed from 
immunization schedule. In Indonesia, one randomized controlled trial was conducted to 
address the burden of Hib disease in Asia. The result indicates a significant reduction in 
clinical pneumonia among vaccinated children compared to non vaccinated children 
(Gessner et al., 2005). However there was no significant reduction among radiologically 
confirmed pneumonia cases. A 34 to 44% risk reduction of radiologically confirmed 
pneumonia was detected in case control study on Hib vaccination from Bangladesh 
(Baqui et al., 2007). Hib vaccine was distributed by use of a quasi-randomized approach 
after adjustment for the confounding factors. Additional evidence on the effectiveness of 
Hib vaccine for pneumonia prevention was seen in other case control studies (Andrade 
et al., 2004; Hoz et al., 2004). 
 
 
 Majority of the available papers available that relate immunization and pneumonia 
were focusing on the association between immunization and pneumonia prevention. 
There were only few studies focusing on lack of immunization as risk factor of 
pneumonia. A study was conducted in Spain using sample size of 1500 cases and 1500 
age and gender matched controls (Almirall et al., 2008).  Strict diagnostic criteria were 
used to ensure correct diagnosis and eliminate bias that may occur due to 
misclassification. They were looking at the association between lower respiratory 
infections and a number of risk factors, including lack or incomplete immunization. The 
study found that there was a significant association between incomplete immunization 
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and the risk of pneumonia. However, further studies need to be done in order to confirm 
this association and to monitor the changes that may occurs due to the periodic alteration 
in the etiology of pneumonia.  
 
1.4.2.3    Low Birth Weight 
Grant (1994) estimated that 19% of all babies born in developing countries have 
low birth weight that is, a birth weight of <2500 g, up to and including 2499g (WHO, 
2005a). The median prevalence ranges from 10% in the Middle East and North Africa to 
34% in southern Asia. There are two main mechanisms that predispose low birth weight 
infants to an increased risk of respiratory infections, these are reduced immuno-
competence and impaired lung function. Low birth weight babies may have a higher 
incidence of pneumonia because low birth weight may lead to a short duration of breast 
feeding and poor nutritional status.  
 
Generally, low birth weight infants may be divided into 2 broad subgroups: preterm 
(<37 wk gestation) and small for gestational age (SGA). The operational definition of 
SGA is an infant born at term with a weight less than the standard reference weight. 
SGA infants are more adversely affected than preterm infants and their impairment lasts 
longer (Hanaa, Nafisa, and Randa, 2011). However, impairment of the immune response 
may arise from nutritional deficits (Yu and Upadhyay, 2004). 
 
Report on the association between low birth weight and pneumonia
 
incidence 
throughout infancy stage is poorly documented. The association between low birth 
weight and respiratory infections (generally) was the focus point in most of the studies 
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that were conducted. Despite the fact that these studies may provide the evidence on the 
association between low birth weight and respiratory infection (Datta et al., 1987; Chen 
et al., 1988; Cerqueiro et al., 1990; Victora et al., 1994; Fonseca et al., 1996), they are 
relatively old. Much of the recent studies involve determination of the association 
between low birth weight and mortality due to respiratory infection, or LBW and 
frequent hospitalization.  
 
A study was conducted to identify risk factors of LRTI associated infant mortality 
in the United States of America. Deaths associated with LRTI were defined as deaths for 
which the International Classification of Diseases, 10th Revision (ICD-10) codes for 
LRTI appeared anywhere on the coded death record. LRTI includes pneumonia and 
influenza (ICD-10 codes J10 –J18). A total of 5420 LRTI associated infant deaths were 
documented in the United States during the period 1999–2004. The conclusion was 
made indicates that low birth weight was associated with markedly increased risk for 
LRTI associated death among all of the racial groups (Rosalyn et al., 2009).  
 
Two studies were conducted to determine if low birth weight is associated with 
hospitalization due to respiratory illness. One American population based case control 
study from Washington was identified two levels of exposure. These are very low birth 
weight (VLBW < 1500 g), and moderately low birth weight (MLBW 1500-2499 g). 
Normal birth weight subjects (2500-4000 g) were considered unexposed. The discharge 
diagnosis codes were used to define respiratory hospitalization. A total of 4674 cases 
and 18445 controls subjects were identified. The controls were age matched to the cases 
and randomly selected. The odds ratio for hospitalization due to respiratory illness was 
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1.83 for VLBW (P = 0.001). For Moderately low birth weight the odds ratio was 1.34 at 
P < 0.005. This was after controlling of the confounding factors like age, sex, marital 
status, residence and race (Eric et al., 2009). Also in Washington, more recent 
population based study of cohort design was conducted to test if low birth weight 
subjects are at increased risk of respiratory disease. Diagnosis was done using ICD-9 
classification. Normal birth weight subjects were randomly selected from birth 
certificates, frequency matched to low birth weight subjects by birth year. Identification 
of the exposed (low birth weight) and unexposed (normal birth weight) subjects was 
done and categorize to VLBW and MLBW. (Odds ratio for hospitalization was 1.39 for 
moderately-low-birth weight (P < 0.001), for very low birth weight 2.52 (p < 0.001). 
They concluded that low birth weight was associated with an increased risk of 
hospitalizations due to respiratory illness (Eric et al., 2011). However, confounding 
factors were not considered and matching for age wasn't done for all paired cases and 
controls as done in the study of Eric et al., 2009.  
 
In short, despite the similarities between the study of Eric et al and this study (case 
control design, diagnosis based on discharge codes, comparing the exposed with 
unexposed through logistic regression). A major different point is that this study 
targeting pneumonia only and not all types of respiratory tract infection as in the case of 
most the studies that were reviewed in this literature 
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1.4.2.4    Preterm Birth 
Preterm birth is an important determinant of neonatal mortality and morbidity 
(Wang et al., 2004). It was advocated that the well-known unfavorable adverse 
outcomes of preterm birth on health would last for a long term and might appear later in 
life (Saigal and Doyle, 2008). The estimates of the year 2005 indicated that about 10% 
(12.9 million births) of all life births worldwide were preterm, 85% (11 million births) of 
which were concentrated in Africa and Asian regions (Stacy et al., 2009). They defined 
preterm birth as child birth occurring at less than 37 completed weeks or within 259 days 
of gestation. Morbidity is adversely related to gestational age as the fetus needs time to 
grow, and to develop its tissues and organs. Therefore, the consequences of preterm 
birth on later health and development during the first two years of life were crucial. It 
was discovered that preterm children had higher prevalence of wheezing and 
hospitalization for the first year of life compared to full term children. However 
pneumonia is more prominent and hospitalization which was reported more frequently 
among preterm birth children compared to children born at term, the study did not search 
long term effects (after the first 2 years of life) of preterm birth on pneumonia and 
hospitalization (Ina et al., 2009). In the current study, the association of preterm birth 
and pneumonia risk were investigated for children up to 5 years old.  
 
1.4.2.5    Low Weight for Age 
Childhood underweight is one of the leading causes of global
 
burden of disease (Ezzati 
et al., 2002), and one of the important risk factors of pneumonia in children (Anone, 
2003). In one case control study to determine the risk factors of pneumonia among 
Indian children, Z score for weight/age based on national center for health statistics data 
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was used to evaluate the implication of weight status on pneumonia risk. Cases were 127 
children aged 2-35 months hospitalized with pneumonia. Controls were 135 children 
attending their immunization clinic. The results indicate that children with a score lower 
than 0 was associated with  more than three folds increase in the risk of pneumonia (OR 
3.26, CI 1.82-5.85) when compared to children with a score equal to or greater than 0, 
even after being adjusted for all the other variables (Mahalanabis et al., 2002). However, 
the controls were healthy children attending immunization clinic and not hospitalized 
children which makes the results prone to recalling bias. In this study, controls were 
hospitalized children.  
 
 During the search in literature, lack of recent studies testing the association of 
low weight fore age and pneumonia risk was one of the obstacles for this study. Most of 
the studies were focusing on the association between malnutrition and risk of pneumonia 
mortality. Underweight (which is represented by weight-for-age z-score < -2) was 
categorized as definite risk factor of pneumonia by WHO (Rudan et al., 2008). The 
evidence that could further supports this association is available on some old and recent 
studies (Agrawal et al., 1995; Banajeh, Sunbali, and Sanahani, 1997; Sehgal et al., 1997; 
Yoon et al., 1997; Man et al., 1998; Bahwere et al., 2004; Caulfield et al., 2004; 
Johnson et al., 2008; Nantanda et al., 2008; Naheed et al., 2009). one of the possible 
explanations for this association is that an underweight child (which is probably due to 
being undernourished) might have impaired immune responses and is more prone to 
infections than a normal weight child who is well nourished (Fanca et al., 2009).  
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1.4.2.6    Day Care Attendance 
Previous epidemiological studies have used
 
day care attendance as an indicator of 
the increased likelihood
 
of early and frequent exposure to infections. It is well 
documented
 
that in developed countries, exposures to common infections
 
occur more 
frequently in institutional settings (Kevin et al., 2008). A study was conducted in 
Denmark to investigate the risk of respiratory and other illnesses among children (age
 
groups: 6 weeks through 17 months, 18 through 35 months, and
 
36 through 59 months) 
who were exposed to various types of day care facilities (Mads et al., 2006). Children 
are considered exposed to day care environment if they were enrolled in day care 
centres, for at least 10 hours per week for the 4 weeks before
 
the interview. Unexposed 
children were not enrolled in any regular
 
child care centre with children and did not have 
siblings
 
younger than 5 years of age who received regular day care. Although an 
increased risk of respiratory illness
 
was associated with the attendance at day care centre 
for children in all three
 
age groups, the risk was statistically significant only for
 
children 
between 6 weeks to 17 months of age (odds ratio = 1.6;
 
95% confidence interval = 1.1 to 
2.4).  
 
 In Brazilian case control study involving 650 Brazilian children aged less than 2 
years. The risk of pneumonia among children attending day care was investigated. They 
found that there was a significant association between the risk of pneumonia among 
young children and day care centre attendance (Fonseca et al., 1997). However, the 
study only recruited the subjects and controls from poor socioeconomic areas, and 
poverty could be a source of other factors (confounding factors) that may lead to the 
increase risk of infection like pneumonia.  
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 Previous studies were investigated the association of daycare centre attendance 
and risk of respiratory infection (Fleming et al., 1987; Hurwitz et al., 1991; Hardy and 
Fowler, 1993; Nafstad et al., 1995; Fuchs et al., 1996; Louhiala et al., 1999; Celedon et 
al., 1999; Forssell, Hakansson, and Mansson, 2001; Anders et al., 2003; Dales et al., 
2004). There should be further studies to evaluate the association between the risk of 
pneumonia among young children and day care centre attendance. Such studies should 
also consider the contribution of other possible confounding factors. This study 
evaluated only pneumonia cases not the other respiratory tract infection. 
 
1.4.2.7    Young Maternal Age  
Another factor that may increase the risk of pneumonia is young maternal age. A 
hospital based case control study was conducted
 
in Southern Brazil to review 510 infants 
of less than two years old with radiological confirmed pneumonia. The incidence of 
radiological confirmed pneumonia was associated with low paternal education, the 
number of persons in the household and young maternal age (Victora et al., 1994). 
Another hospital based case control study was conducted by Luiz et al., (2004), in 
Taubate University Hospital Brazil, they classified mother’s age under 3 categories: less 
than 20 years, 20 to 34, and over 34 years old. The study found that young maternal age 
was one of the statistically significant risk factors. Therefore, younger mothers have 
twice as likely to have a child being hospitalized due to pneumonia compared to mothers 
who were within the range of 20 to 34 years of age. The possible explanation is that 
early motherhood puts young women at risk for educational underachievement 
(Nanchahal et al., 2005; Hofferth, Reid, and Mott, 2001), and poorer economic 
circumstances which represented by higher levels of welfare dependence, lower levels of 
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workforce participation, and lower income (Moffitt, 2002; Olauson et al., 2001). In 
addition early motherhood is associated with higher levels of mental health disorders 
(Schmidt et al., 2006; Boden et al., 2008). All these factors will absolutely have negative 
role in child health rendering him more prone to infection (Hofferth and Reid, 2002). In 
the above mentioned studies, pneumonia diagnosis was merely based on radiographic 
finding, hence the diagnosis might be not accurate as compared to set of diagnostic tools 
including confirmed culture. 
 
1.4.2. 8    Parental Smoking 
Another significant risk factor for childhood pneumonia is parental smoking (Broor 
et al., 2001; Haberg et al., 2007; Duijts et al., 2008; Puig et al., 2009). Smoking has 
many undesirable effects, not only to the smokers, but also to others who inhale the 
smoke known as passive smokers. Besides, parental smoking might have an affect on 
children’s health either directly or indirectly causing infection. The direct mechanisms 
by which smoking increases the risk of infections include structural changes in the 
respiratory tract and a decrease in the immune response (Lidia and Neal, 2004; Noakes 
et al., 2007; Ruskamp et al., 2010). A study revealed that smokers incur a 2 to 4 fold 
increased risk of invasive pneumococcal disease (Satoru et al., 2005). Children of 
parents who smoke have higher frequency of hospitalization for bronchitis and 
pneumonia during the first year of life when compared to the children of nonsmoker 
parents (Braback , Bjor, and Nordahl, 2003; Al-Shehri, Sadeq, and Quli, 2005; Carroll et 
al., 2007; Suzuki et al., 2009). 
 
